A phase II study of GW572016 [lapatinib] and tamoxifen in patients with metastatic breast cancer resistant to single-agent tamoxifen.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2015
At a glance
- Drugs Lapatinib (Primary) ; Tamoxifen (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 19 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 08 Aug 2011 Planned end date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.